Added Value of PET/CT in Lung Cancer

NCT06494800 | Not Yet Recruiting

• 1 other identifier: PET/CT in lung cancer
• Study Type: observational
• Target: 30
• Locations: 0 countries
• Sites: N/A

Brief Summary

Assess the value of PET/CT in the diagnosis, staging, response evaluation, and relapse monitoring of lung cancer.

Conditions

Lung Cancer

Keywords

PET-CT; lung cancer

Outcome Measures

Primary Outcomes (4)

• Accuracy of PET CT in diagnosis of lung cancer

  using the qualitative and quantitative measuring including the SUV max value in detection of the malignant potentiality of the pulmonary nodule or mass comparing it with the pathological result

  1 Year

• Value of PET CT in staging of lung cancer

  using the PET CT in TNM staging with better detection of pleural , mediastinal extension /involvement, the value and accuracy of PET in detecting the potential malignancy of the mediastinal lymph nodes even the subcentemetric lymph nodes not adequately assessed by the usual CT.

  1 Year

• predicting the pathological subtype of lung cancer using the morphological and PET CT of pathologically proved lung masses

  assessing the morphology of the lung mass including density, solid, subsolid and soft nodule. site of the nodule/mass peripheral or centrally located. presence of cavitation or cystic changes. presence of speculated or irregular margin. measuring the SUV max and comparing it with the pathology of each mass/nodule.

  1 Year

• Differentiating between the primary mass and associated consolidation if present

  using the PET CT (mainly the qualitative assessment) in differentiating the primary mass from the associated consolidation-atelectasis around

  1 Year

Secondary Outcomes (3)

• assessment of the pleural thickening/effusion associated with the primary mass

  1 Year

• presence of enlarged axillary Lns

  1 Year

• assessing the Vocal cord paralysis in the pan-coast tumor

  1 Year

Study Arms (1)

pathologically proved lung cancer patient

All the pathologically proved lung cancer patients by true cut needle biobsy are enrolled in the study. the true cute needle biobsy procedure performed by two interventional radiologists and a pathologist. TCNB was guided by the use of a 16-detector CT device after local anesthesia is done and done either by ultrasound guidance or CT guidance.

Diagnostic Test: True cut needle biobsy

Interventions

True cut needle biobsy DIAGNOSTIC_TEST

The biobsy procedure done at the radiology department and the cores are examined by the pathology department, the patient lie prone, supine or in lateral decubitus according to the location of the lesion. A thoracic CT scan was performed first to evaluate the needle pathway and distance from the puncture site to the lesion. The needle pathway was selected to avoid bone, visible vessels, bullae, and fissures. The puncture site was chosen by the CT gantry laser lights and landmarks using a homemade radiopaque grid on the patient's skin. Local anaesthesia was induced with 5 mL of 2% lidocaine. An 18-G coaxial needle was used to puncture the lung, and a repeat CT scan was performed to evaluate the site of the needle. When the needle tip reached the lesion, the specimen was obtained by pressing the trigger of the needle. The specimen was reviewed by the pathologist.The specimen was placed in 10% formaldehyde for pathological examination.

Also known as: TCNB

pathologically proved lung cancer patient

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All the pathologically proved lung cancer patient in the oncology department at the sohag oncology Centre.

You may qualify if:

• Pathologically proven lung cancer patients.

You may not qualify if:

• Patients with second malignancy.
• Severely ill patient (patient with disturbed consciousness level, or couldn't lie during the imaging).
• Uncontrolled diabetic patient with blood glucose level more than 200mg\\dl.
• Pregnant women.
• Patient age \<18 years.

Sponsors & Collaborators

• Sohag University: lead

Related Publications (4)

• Archer JM, Truong MT, Shroff GS, Godoy MCB, Marom EM. Imaging of Lung Cancer Staging. Semin Respir Crit Care Med. 2022 Dec;43(6):862-873. doi: 10.1055/s-0042-1753476. Epub 2022 Jul 10.

  PMID: 35815631 BACKGROUND

• Laguna JC, Garcia-Pardo M, Alessi J, Barrios C, Singh N, Al-Shamsi HO, Loong H, Ferriol M, Recondo G, Mezquita L. Geographic differences in lung cancer: focus on carcinogens, genetic predisposition, and molecular epidemiology. Ther Adv Med Oncol. 2024 Mar 6;16:17588359241231260. doi: 10.1177/17588359241231260. eCollection 2024.

  PMID: 38455708 BACKGROUND

• Panunzio A, Sartori P. Lung Cancer and Radiological Imaging. Curr Radiopharm. 2020;13(3):238-242. doi: 10.2174/1874471013666200523161849.

  PMID: 32445458 BACKGROUND

• Kandathil A, Subramaniam RM. FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma. Semin Nucl Med. 2022 Nov;52(6):650-661. doi: 10.1053/j.semnuclmed.2022.04.011. Epub 2022 Jun 20.

  PMID: 35738910 BACKGROUND

Related Links

• Contrast computed tomography versus PET/CT in the assessment of bronchogenic carcinoma
• Role of CT in differentiation between subtypes of lung cancer; is it possible?
• PET-CT in Lung Cancer
• FDG-PET/CT tumor to liver SUV ratio (TLR), tumor SUVmax, and tumor size: Can this help in differentiating squamous cell carcinoma from adenocarcinoma of the lung?

MeSH Terms

Conditions

Lung Neoplasms

Condition Hierarchy (Ancestors)

Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• mai sayed khalifa, MD

  lecturer

  PRINCIPAL INVESTIGATOR

• doaa ibrahim mohamed, MD

  lecturer

  PRINCIPAL INVESTIGATOR

Central Study Contacts

mennatallah ahmed raghib, M.B.B.Ch

CONTACT

01115499811; menna.ragheb@med.sohag.edu.eg

wafaa abdelhamid elsayed, MD

CONTACT

01113111278; wafaaagraby@yahoo.com

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: resident, nuclear and oncology medicine department, Sohag university

Study Record Dates

• First Submitted: July 2, 2024
• First Posted: July 10, 2024
• Study Start: July 15, 2024
• Primary Completion: July 15, 2025
• Study Completion: December 1, 2025
• Last Updated: July 10, 2024

Record last verified: 2024-07